Characterising treatment outcomes of patients achieving quarterly aflibercept dosing for neovascular age-related macular degeneration: real-world clinical outcomes from a large tertiary care centre

Background and objective To evaluate the proportion of patients achieving a 12-week (q12) aflibercept dosing interval in patients with neovascular age-related macular degeneration (nAMD). Patients and methods Retrospective, comparative, non-randomised electronic medical record (EMR) database study o...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Eye (London) 2023-03, Vol.37 (4), p.779-784
Hauptverfasser:	Fu, Dun Jack, Hanumunthadu, Daren, Keenan, Tiarnan D. L., Wagner, Siegfried, Balsakas, Konstantinos, Keane, Pearse A., Patel, Praveen J.
Format:	Artikel
Sprache:	eng
Schlagworte:	692/53/2423 692/699/3161/1626 Acuity Age Angiogenesis Inhibitors - therapeutic use Dosage Electronic medical records Eye Female Humans Infant Injection Intravitreal Injections Laboratory Medicine Macular degeneration Macular Degeneration - drug therapy Male Medicine Medicine & Public Health Ophthalmology Patients Pharmaceutical Sciences/Technology Receptors, Vascular Endothelial Growth Factor Recombinant Fusion Proteins - therapeutic use Retrospective Studies Surgery Surgical Oncology Tertiary Care Centers Treatment Outcome Vascular endothelial growth factor Visual acuity Wet Macular Degeneration - diagnosis Wet Macular Degeneration - drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!